Warner Chilcott win upheld by Third Circuit in Doryx 'product hopping' appeal
Product-hopping — where a branded drugmaker makes incremental changes to a drug to extend its patent protection — can be anticompetitive in some cases, but Mylan didn’t offer enough evidence that Warner Chilcott's...To view the full article, register now.
Already a subscriber? Click here to view full article